Business
Crescita Awarded Cannabis Research License from Health Canada
Crescita Awarded Cannabis Research License from Health Canada Canada NewsWire LA...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Awarded Cannabis Research License from Health Canada\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nLAVAL, QC, Jan. 24, 2020\n\n\n\nLAVAL, QC, Jan. 24, 2020 /CNW Telbec/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (\"Crescita\" or the \"Company\"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is pleased to announce that its wholly-owned subsidiary, INTEGA Skin Sciences Inc. (\"INTEGA\") has been awarded a cannabis research license (the \"Research License\") by Health Canada under the Cannabis Act and Cannabis Regulations, allowing the Company to possess cannabis for the purpose of research and development (\"R&D\"). \n\n \n \n\n \nThe Research License is effective immediately and will enable the Company to better support the needs of its existing partnerships in the cannabis industry through innovation-driven product development. The Research License is also expected to accelerate R&D programs and reduce the time to market. \nThe Company also intends to develop cannabinoid-infused topical product formulations under its own skincare brands, and may do so using its proprietary transdermal delivery technologies at its Laval, Québec facility. \nSerge Verreault, Crescita's President and CEO commented: \"The issuance of the Research License represents an important milestone in Crescita's strategic plan. We will now be able to perform in-house development of new cannabinoid based topical products and create patentable science-driven innovation in skincare solutions.\" Mr. Verreault added: \"I am confident that Crescita will secure a healthy piece of this market segment creating new revenue streams for the Company.\"\n\"We are excited about the opportunity to expand our product development and innovation efforts,\" said Isabelle Villeneuve, Vice-President, Strategy, Quality and Innovation. \"The Research License opens up many R&am...